Results 71 to 80 of about 6,419 (213)

COVID-19: Variants, Immunity, and Therapeutics for Non-Hospitalized Patients [PDF]

, 2023
The continuing transmission of coronavirus disease 2019 (COVID-19) remains a world-wide 21st-century public health emergency of concern. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused greater than 600 million cases of COVID-19 ...
Lee, Cameron, Lee|, suzuki, jon, Suzuki|
core   +1 more source

COVID‐19 Antiviral Treatment: Examining Knowledge, Access, Trust in Sources of Information and Willingness to Use Among Essential Workers: A Cross‐Sectional Survey of Cohort Participants

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Despite evidence of effectiveness, oral antivirals for COVID‐19 are underused, with significant variation across populations. This study examines COVID‐19 treatment awareness, knowledge, access, trusted sources, and willingness to use among diverse essential workers in Tennessee during May 18, 2023–June 1, 2024.
Jenae Sanders, Jade James‐Gist, Melisa M. Shah, Nathan Graff, Olivia Almendares, Tiffany Israel, Yuwei Zhu, Bryan Blette, Sarah Hamid, Hope King, H. Keipp Talbot, Carlos G. Grijalva, Melissa Briggs‐Hagen   +12 more
wiley   +1 more source

COVID‐19 Prophylactic Effect of Bromhexine Hydrochloride

Immunity, Inflammation and Disease, Volume 14, Issue 4, April 2026.
ABSTRACT Introduction Despite extensive efforts to identify effective treatments for COVID‐19, preventive strategies remain essential. Bromhexine hydrochloride (BRH), an over‐the‐counter mucolytic with potential TMPRSS2 inhibition, may reduce viral entry and thus serve as a prophylactic agent.
Vanyo Mitev, Tsanko Mondeshki, Ani Miteva, Konstantin Tachkov, Violeta Dimitrova   +4 more
wiley   +1 more source

Evaluating Drug Interaction Risks: Nirmatrelvir & Ritonavir Combination (PAXLOVID^®) with Concomitant Medications in Real-World Clinical Settings

Pathogens
Background: This research article delves into the battle against the COVID-19 pandemic, focusing on the efficacy and, particularly, the safety of the combination of nirmatrelvir with ritonavir, which is found in the pharmaceutical product Paxlovid®. This
Petra Zatovkaňuková, Dalibor Veselý, Jiří Slíva   +2 more
doaj   +1 more source

Native American Pregnant and Postpartum People's Experiences of Discrimination During Perinatal Care: A Qualitative Study

BJOG: An International Journal of Obstetrics &Gynaecology, Volume 133, Issue 5, Page 1026-1036, April 2026.
ABSTRACT Objective Indigenous pregnant and postpartum people are more likely to experience severe maternal morbidity (SMM) and mortality than non‐Indigenous groups. We sought to explore how community and societal factors, culture, and resilience impact Native American individuals' pregnancy experiences and might offer insights to address inequities in ...
Jennifer L. Murray, Heather Tanana, Torri D. Metz, Reham Perry, Elisabeth R. Kimball, Patrick Galyean, Susan Zickmund, Michael W. Varner, Michelle P. Debbink   +8 more
wiley   +1 more source

Insights from a community-based survey on factors influencing acceptance and uptake of Paxlovid (nirmatrelvir and ritonavir) as a COVID-19 antiviral medication in Singapore

BMC Public Health
Introduction Antiviral treatment can reduce the burden of COVID-19. But utilisation can be suboptimal, even in a setting like Singapore where it is fully subsidized for those with selected medical conditions and older adults (≥ 50 years).
Sheng En Alexius Matthias Soh, Wei Ling Brenda Ong, Tun-Linn Thein, Konstadina Griva, I.-Cheng Mark Chen   +4 more
doaj   +1 more source

Antivirals Targeting Coronavirus RNA‐Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID‐19 Clinical Trials

Microbial Biotechnology, Volume 19, Issue 4, April 2026.
The target sites of COVID‐19 antivirals discussed in the present opinion paper, namely the RNA dependent RNA polymerase Nsp12 and of the main viral protease Nsp5, are indicated by a red star in the overview of the replication cycle of coronavirus SARS‐CoV‐2.
Harald Brüssow
wiley   +1 more source

Network medicine and systems pharmacology approaches to predicting adverse drug effects

British Journal of Pharmacology, Volume 183, Issue 8, Page 1627-1639, April 2026.
Identifying and understanding the relationships between drug intake and adverse effects that can occur due to inadvertent molecular interactions between drugs and targets is a difficult task, especially considering the numerous variables that can influence the onset of such events.
Alessio Funari, Giulia Fiscon, Paola Paci   +2 more
wiley   +1 more source

Studying the efficacy of Nirmatrelvir and Ritonavir (Paxlovid) for outpatient treatment of COVID-19 in the pediatric population using real-world data from the National COVID Cohort Collaborative (N3C) [PDF]

This study analyzes the efficacy of Nirmatrelvir and Ritonavir (NMV-r; Paxlovid) for outpatient treatment of COVID-19 in the pediatric population in the age group 12-18 years by using real-world data from N3C. The study uses propensity matching to create
Kumar, Manish
core   +1 more source

Reduced Mortality in COVID‐19 Patients Treated With Inhaled Extracellular Vesicles Expressing CD24

Journal of Extracellular Vesicles, Volume 15, Issue 3, March 2026.
ABSTRACT Background: Severe COVID‐19, and other systemic infections, can trigger hyperinflammation leading to lung injury. EXO‐CD24, an inhaled extracellular vesicle therapy with anti‐inflammatory properties, has shown acute clinical benefit, but long‐term effects on survival remain unknown.
Shiran Shapira, Guy Vishnevsky, Hadas Yaakobi, Gil Shenberg, Mays Motlaq, Eliezer Liberman, Aminadav Kalisky, Gadi Benari, Sotirios Tsiodras, Nimrod Adi, Jan Lötvall, Nadir Arber   +11 more
wiley   +1 more source